Cargando…

Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function

Plasma clearance of iohexol is a pivotal metric to quantify glomerular filtration rate (GFR), but the optimal timing and frequency of plasma sampling remain to be assessed. In this study, we evaluated the impact of a Bayesian estimation procedure on iohexol clearance estimates, and we identified an...

Descripción completa

Detalles Bibliográficos
Autores principales: Taubert, Max, Schaeffner, Elke, Martus, Peter, van der Giet, Markus, Fuhr, Uwe, Lösment, Amina, Ebert, Natalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608910/
https://www.ncbi.nlm.nih.gov/pubmed/34811403
http://dx.doi.org/10.1038/s41598-021-01892-1
_version_ 1784602831989243904
author Taubert, Max
Schaeffner, Elke
Martus, Peter
van der Giet, Markus
Fuhr, Uwe
Lösment, Amina
Ebert, Natalie
author_facet Taubert, Max
Schaeffner, Elke
Martus, Peter
van der Giet, Markus
Fuhr, Uwe
Lösment, Amina
Ebert, Natalie
author_sort Taubert, Max
collection PubMed
description Plasma clearance of iohexol is a pivotal metric to quantify glomerular filtration rate (GFR), but the optimal timing and frequency of plasma sampling remain to be assessed. In this study, we evaluated the impact of a Bayesian estimation procedure on iohexol clearance estimates, and we identified an optimal sampling strategy based on data in individuals aged 70+. Assuming a varying number of random effects, we re-estimated previously developed population pharmacokinetic two- and three-compartment models in a model development group comprising 546 patients with iohexol concentration data up to 300 min post injection. Model performance and optimal sampling times were assessed in an evaluation group comprising 104 patients with reduced GFR and concentration data up to 1440 min post injection. Two- and three-compartment models with random effects for all parameters overestimated clearance values (bias 5.07 and 4.40 mL/min, respectively) and underpredicted 24-h concentrations (bias − 14.5 and − 12.0 µg/ml, respectively). Clearance estimates improved distinctly when limiting random effects of the three-compartment model to clearance and central volume of distribution. Two blood samples, one early and one 300 min post injection, were sufficient to estimate iohexol clearance. A simplified three-compartment model is optimal to estimate iohexol clearance in elderly patients with reduced GFR.
format Online
Article
Text
id pubmed-8608910
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86089102021-11-24 Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function Taubert, Max Schaeffner, Elke Martus, Peter van der Giet, Markus Fuhr, Uwe Lösment, Amina Ebert, Natalie Sci Rep Article Plasma clearance of iohexol is a pivotal metric to quantify glomerular filtration rate (GFR), but the optimal timing and frequency of plasma sampling remain to be assessed. In this study, we evaluated the impact of a Bayesian estimation procedure on iohexol clearance estimates, and we identified an optimal sampling strategy based on data in individuals aged 70+. Assuming a varying number of random effects, we re-estimated previously developed population pharmacokinetic two- and three-compartment models in a model development group comprising 546 patients with iohexol concentration data up to 300 min post injection. Model performance and optimal sampling times were assessed in an evaluation group comprising 104 patients with reduced GFR and concentration data up to 1440 min post injection. Two- and three-compartment models with random effects for all parameters overestimated clearance values (bias 5.07 and 4.40 mL/min, respectively) and underpredicted 24-h concentrations (bias − 14.5 and − 12.0 µg/ml, respectively). Clearance estimates improved distinctly when limiting random effects of the three-compartment model to clearance and central volume of distribution. Two blood samples, one early and one 300 min post injection, were sufficient to estimate iohexol clearance. A simplified three-compartment model is optimal to estimate iohexol clearance in elderly patients with reduced GFR. Nature Publishing Group UK 2021-11-22 /pmc/articles/PMC8608910/ /pubmed/34811403 http://dx.doi.org/10.1038/s41598-021-01892-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Taubert, Max
Schaeffner, Elke
Martus, Peter
van der Giet, Markus
Fuhr, Uwe
Lösment, Amina
Ebert, Natalie
Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function
title Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function
title_full Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function
title_fullStr Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function
title_full_unstemmed Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function
title_short Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function
title_sort advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608910/
https://www.ncbi.nlm.nih.gov/pubmed/34811403
http://dx.doi.org/10.1038/s41598-021-01892-1
work_keys_str_mv AT taubertmax advancementofpharmacokineticmodelsofiohexolinpatientsaged70yearsorolderwithimpairedkidneyfunction
AT schaeffnerelke advancementofpharmacokineticmodelsofiohexolinpatientsaged70yearsorolderwithimpairedkidneyfunction
AT martuspeter advancementofpharmacokineticmodelsofiohexolinpatientsaged70yearsorolderwithimpairedkidneyfunction
AT vandergietmarkus advancementofpharmacokineticmodelsofiohexolinpatientsaged70yearsorolderwithimpairedkidneyfunction
AT fuhruwe advancementofpharmacokineticmodelsofiohexolinpatientsaged70yearsorolderwithimpairedkidneyfunction
AT losmentamina advancementofpharmacokineticmodelsofiohexolinpatientsaged70yearsorolderwithimpairedkidneyfunction
AT ebertnatalie advancementofpharmacokineticmodelsofiohexolinpatientsaged70yearsorolderwithimpairedkidneyfunction